Key Documents

View All Documentation

A7655

Atenolol

Name: Atenolol
Brand: SIGMA

≥98% (TLC), powder, β₁-adrenoceptor antagonist

Synonym(s):

(±)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide, 4-[2′-Hydroxy-3′-(isopropylamino)propoxy]phenylacetamide

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₄H₂₂N₂O₃

CAS Number:

29122-68-7

Molecular Weight:

266.34

NACRES:

NA.77

PubChem Substance ID:

24277748

UNSPSC Code:

12352200

EC Number:

249-451-7

MDL number:

MFCD00057645

Assay:

≥98% (TLC)

Form:

powder

Quality level:

200

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Product Name

Atenolol, ≥98% (TLC), powder

Quality Level

200

assay

≥98% (TLC)

form

powder

color

white to off-white

solubility

H₂O: 0.3 mg/mL, DMSO: 18 mg/mL, ethanol: 3.4 mg/mL

originator

AstraZeneca

SMILES string

CC(C)NCC(O)COc1ccc(CC(N)=O)cc1

InChI

1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)

InChI key

METKIMKYRPQLGS-UHFFFAOYSA-N

Gene Information

human ... ADRB1(153)
rat ... Adrb1(24925)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Bioactive Small Molecules

Application

Atenolol is a β-adrenergic blocker and used in the management of hypertension. Atenolol has antianginal and antiarrhythmic properties.

Biochem/physiol Actions

Selective β₁-adrenoceptor antagonist; antihypertensive; antianginal; antiarrhythmic.

Features and Benefits

This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Other Notes

Shelf-life of the solid is at least three years.

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

监管及禁止进口产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis.

Ganesha Rai et al.

Journal of medicinal chemistry, 52(20), 6474-6483 (2009-09-19)

Schistosomiasis is a chronic parasitic disease affecting hundreds of millions of individuals worldwide. Current treatment depends on a single agent, praziquantel, raising concerns of emergence of resistant parasites. Here, we continue our explorations of an oxadiazole-2-oxide class of compounds we

Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.

Hsin-Hui Chiu et al.

Mayo Clinic proceedings, 88(3), 271-276 (2013-01-17)

To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS). Between May 1, 2007, and September 31

Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy.

Ronald V Lacro et al.

American heart journal, 165(5), 828-835 (2013-04-30)

The Pediatric Heart Network designed a clinical trial to compare aortic root growth and other short-term cardiovascular outcomes in children and young adults with Marfan syndrome randomized to receive atenolol or losartan. We report here the characteristics of the screened

Atenolol versus losartan in children and young adults with Marfan's syndrome.

Ronald V Lacro et al.

The New England journal of medicine, 371(22), 2061-2071 (2014-11-19)

Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers. We conducted a randomized trial comparing

Vitamin B Mitigates Thoracic Aortic Dilation in Marfan Syndrome Mice by Restoring the Canonical TGF-β Pathway.

Tzu-Heng Huang et al.

International journal of molecular sciences, 22(21) (2021-11-14)

Thoracic aortic aneurysm (TAA) formation is a multifactorial process that results in diverse clinical manifestations and drug responses. Identifying the critical factors and their functions in Marfan syndrome (MFS) pathogenesis is important for exploring personalized medicine for MFS. Methylenetetrahydrofolate reductase

View All Related Papers

Global Trade Item Number

SKU	GTIN
A7655-10G	04061832269078
A7655-5G	04061833386057
A7655-1G	04061833386040
A7655-25G	04061832088716

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service